Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions by Gomez-Barrena, E. et al.
ARTICLE IN PRESS 
JID: JINJ [m5G; March 1, 2020;4:37 ] 
Injury xxx (xxxx) xxx 
Contents lists available at ScienceDirect 
Injury 
journal homepage: www.elsevier.com/locate/injury 
Early efficacy evaluation of mesenchymal stromal cells (MSC) 
combined to biomaterials to treat long bone non-unions  
Enrique Gómez-Barrena a , ∗, Norma Padilla-Eguiluz a , Philippe Rosset b , Florian Gebhard c , 
Philippe Hernigou d , Nicola Baldini e , Helène Rouard d , f , Luc Sensebéf , g , 
Rosa-María Gonzalo-Daganzo h , Rosaria Giordano i , Eduardo García-Rey a , 
José Cordero-Ampuero j , Juan Carlos Rubio-Suárez a , Marta Dominguez García-Simón a , 
Julien Stanovici b , Christian Ehrnthaller c , Markus Huber-Lang c , 
Charles Henri Flouzat-Lachaniette d , Nathalie Chevallier d , f , Davide Maria Donati e , 
Benedetta Spazzoli e , Gabriela Ciapetti e , Sandrine Fleury f , g , Manuel-Nicolás Fernandez h , 
José-Rafael Cabrera h , Cristina Avendaño-Soláh , Tiziana Montemurro i , Carmen Panaitescu k , 
Elena Veronesi l , Markus Thomas Rojewski m , Ramin Lotfim , Massimo Dominici l , 
Hubert Schrezenmeier m , Pierre Layrolle n 
a Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P °
Castellana 261, 2804, Madrid, Spain 
b Service de Chirurgie Orthopédique et Traumatologique 2, Hôpital Trousseau, Université François-Rabelais de Tours, CHU de Tours, Tours, France 
c Department of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Center of Surgery, University of Ulm, Ulm, Germany 
d Orthopaedic Department, Hôpital Henri Mondor, InsermU955 and UPEC (University Paris-Est, Créteil), Créteil, France 
e Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, and Dept. of Biomedical and Neuromotor Sciences, 
University of Bologna, Bologna, Italy 
f Établissement Français du Sang, Paris, France 
g STROMA Lab, UMR5273-INSERM U1031, Toulouse, France 
h Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, and Universidad Autónoma de Madrid, Madrid, Spain 
i Cell Factory, Center for Cellular Therapy and Cryobiology, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy 
j Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Princesa and Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, 
Spain 
k Victor Babes University of Medicine and Pharmacy, Timisoara, Romania 
l Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences for Children & Adults, University - Hospital of Modena and Reggio Emilia, 
Modena, Italy 
m Institut for Transfusion Medicine, Ulm University, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood 
Transfusion Service and University Hospital Ulm, Ulm, Germany 
n INSERM U957, Lab. Pathophysiology of bone resorption, Faculty of Medicine, University of Nantes, Nantes, France 
a r t i c l e i n f o 
Article history: 
Accepted 15 February 2020 
Available online xxx 
Keywords: 
Non-union 
Long Bone 
Treatment 
MSC 
Bioceramics 
Efficacy 
Clinical Consolidation 
Radiological Consolidation 
a b s t r a c t 
Background and study aim: Advanced therapy medicinal products (ATMP) frequently lack of clinical data 
on efficacy to substantiate a future clinical use. This study aims to evaluate the efficacy to heal long 
bone delayed unions and non-unions, as secondary objective of the EudraCT 2011-005441-13 clinical trial, 
through clinical and radiological bone consolidation at 3, 6 and 12 months of follow-up, with subgroup 
analysis of affected bone, gender, tobacco use, and time since the original fracture. 
Patients and methods: Twenty-eight patients were recruited and surgically treated with autologous bone 
marrow derived mesenchymal stromal cells expanded under Good Manufacturing Practices, combined to 
bioceramics in the surgical room before implantation. Mean age was 39 ± 13 years, 57% were males, and 
mean Body Mass Index 27 ± 7. Thirteen (46%) were active smokers. There were 11 femoral, 4 humeral, 
and 13 tibial non-unions. Initial fracture occurred at a mean ± SD of 27.9 ± 31.2 months before recruit- 
ment. Efficacy results were expressed by clinical consolidation (no or mild pain if values under 30 in 
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1Introduction 
Non-union represents a serious fracture complication due to
associated morbidity, repeated hospitalization, and significant re-
source consumption. Its incidence is highly variable but may rep-
resent over 5% of long-bone fractures. Fracture evolution to delayed
union and non-union is related to timely healing failure. Although
the criteria are debatable, certain consensus has been reached in
defining the non-union if bone healing is not obtained after more
than nine months since the fracture, with more than 3 months
without bone healing progression [1] . The physiological mecha-
nism of bone healing [2] , supported by current treatments, is capa-
ble of solving over 90% of bone injuries. In case of failure to com-
plete bone healing, pain and disability subsequently impair the pa-
tient’s quality of life and limit patient’s work activities. 
Complex fractures, associated to severe traumatic injuries such
as traffic accidents [3] , frequently produce secondary limitations,
ranging from 40 to 70% of patients [4] . Functional capacity and
quality of life in survivors of severe injuries often do not recover
even one year after trauma, female gender and comorbidity being
predictors of long-term disability. 
The development of alternative solutions to enhance healing
through bone regeneration [5] , particularly in complex settings
such as non-unions, is a challenging aim with modest results and
scarce clinical confirmation so far [6] . Treatment based on culture-
expanded autologous mesenchymal stromal cells (MSC) associated
with biomaterials fulfils the requisites of osteogenesis, osteoinduc-
tion and osteoconduction. However, the literature and the declared
clinical trials show not only a highly variable methodology, but
also underreported results [6] . At this point, data may be insuffi-
cient to define and support the clinical application of regenerative
medicine solutions in patients, and more clinical information on
efficacy is required to understand treatment indications. 
In this context, a phase I/IIa open, prospective, multicen-
tric, non-comparative interventional clinical trial (EudraCT 2011-
005441-13) was recently completed to evaluate safety and feasi-
bility as primary endpoints [7] . This trial evaluated an Advanced
Therapy Medicinal Product –ATMP– (autologous expanded human
Mesenchymal Stromal Cells –hMSCs– from Bone Marrow –BM–)
combined to a CE-marked bioceramic in patients with long bone
fractures status delayed union and non-union. The ATMP (between
100 × 10 6 and 200 × 10 6 expanded hBM-MSC) was produced in
manufacturing centers approved by the National Competent Au-
thority of each participating country, following the same Good
Manufacturing Practice (GMP) protocol. Primary outcome resultsPlease cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ ,consolidation with a REBORNE score over 11/16 points (value of or above
ly compared and mixed models for repeated measurements estimated the
 (95%) of the REBORNE Bone Healing scale. Clinical and radiological con-
 subgroups with Spearman correlation tests (adjusted by Bonferroni). 
was earlier confirmed, while radiological consolidation at 3 months was
s 67.8% (19/28 cases), and at 12 months, 92.8% (26/28 cases including the
failures). Bone biopsies confirmed bone formation surrounding the bioce-
wed similar consolidation, although this was delayed in tibial non-unions.
e was found in 12-month consolidation (95% confidence). Higher consoli-
n non-smoking patients at 6 ( p = 0.012, t -test) and 12 months ( p = 0.011,
er the initial fracture did not preclude the occurrence of consolidation. 
 was efficaciously obtained with the studied expanded hBM-MSCs com-
l and radiological evaluation, and confirmed by bone biopsies, with lower
. 
© 2020 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license.
( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
onfirmed that no severe adverse events were considered related
o the ATMP. No tumorous condition or cell related overgrowth
as detected in patients after cell implantation. From the cell
roduction perspective, feasibility evidence of GMP, multicentric,
quivalent cell production of expanded BM-hMSC was confirmed
nd reported [7] . However, efficacy as a secondary endpoint and
elated to patient and fracture characteristics may offer important
nformation to better understand the possibilities of this treatment.
This study aims to evaluate the efficacy (secondary objective)
o heal patients with long bone delayed unions and non-unions
minimum of 3 months after the acute fracture) in the EudraCT
011-005441-13 clinical trial. Efficacy was evaluated through the
nalysis of clinical and radiological bone consolidation at 3, 6 and
2 months of follow-up, with subgroup analysis uncovered by the
linical trial. 
atients and methods 
Twenty-eight patients were recruited and surgically treated
 Fig. 1 ) with GMP expanded hBM-MSCs combined to MBCP + TM ,
 100% synthetic CE-marked (Biomatlante, Vigneux, France) bone
ubstitute composed of 20% Hydroxyapatite (HA) and 80% beta
ricalcium phosphate (ß-TCP), in 1-2 mm granules. The cell-
iomaterial association was performed in the surgical room before
mplantation. Treatment was performed within the ORTHO1 clin-
cal trial (EudraCT 2011-005441-13) incorporated to the database
linicalTrials.gov with the identifier NCT01842477. Four Ethic Com-
ittees of clinical research (La Paz Hospital CEIC, Madrid, Spain;
PP Tours Région Centre Ouest 1, Tours, France; Ulm University EC,
lm, Germany; and Istituto Ortopedico Rizzoli EC, Bologna, Italy)
pproved the protocol and related documents for all participating
linical centers. As an ATMP for human use, the trial was autho-
ized by the National Competent Authorities (AEMPS, Spain; ANSM,
rance; PEI, Germany; AIFA, Italy) as per Directive 2001/20/EC and
005/28/EC of the European Parliament. The CONSORT diagram
nd the inclusion and exclusion criteria have been published with
he primary outcome of the clinical trial [7] . 
atients and trauma characteristics 
The mean age of the 28 treated patients was 39 ± 13 years,
7% were males, and the mean Body Mass Index (BMI) was 27 ± 7.
hirteen cases (46%) reported active use of tobacco, with a mean of
wo packs daily, and two more were former smokers. There were
1 femoral, 4 humeral, and 13 tibial non-unions in the study. . Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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Fig. 1. (a) surgical preparation of the nonunion site including ablation of necrotic 
free bone fragments, excision of fibrous tissue and/or decortication of bone ends to 
bleeding bone; (b) combined biomaterial – cell product with a pasty consistency, 
fixed to the full extent of the prepared area as for spongy bone. 
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 The original fracture originated from a traffic accident in 67% of
he cases (19/28), and 40% (11/28) were open fractures, 8 in the
ibia and 3 in the femur. The original open fracture was less severe
ith wounds under 1cm (Gustilo I) in 4 tibial and 2 femoral non-
nions. The open fracture was more severe with wounds larger
han 1cm (Gustilo II, III) in 4 tibial and 1 femoral non-union. No
ignificant differences were found among affected bones for demo-
raphic and trauma characteristics ( Table 1 ). 
Regarding the fracture site, distal third of the diaphysis was
he most common fracture location for the femur (4/11) and the
ibia (7/13), followed by the middle third of the diaphysis in femur
3/11), humerus (2/4) and tibia (5/13). Fractures in the proximal
hird of the diaphysis occurred in 1 tibia (1/13), humerus (2/4) and
emur (1/11). Metaphysis or metaphysodiaphyseal regions (2 distal
nd 1 proximal) were involved in 3 femur non-unions. The AO di-
physeal fracture classification (A Simple/B Wedge/C Complex), for
emur was 3/3/2, for humerus 1/0/3, and for tibia 2/6/5. The AO
etaphyseal fracture classification (A Simple/B Wedge/C Complex)
f the 3 femoral cases was 1/0/2. 
The initial fracture occurred at a mean ± SD of 27.9 ± 31.2
onths before recruitment, and the last operation occurred at a
ean ± SD of 14.9 ± 9.9 months before cell therapy. Previous
reatments included 5 cases with intramedullary nail (N), 3 cases
ith plate (P) and 3 cases with external fixation (EF) at the femur.Please cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ , Injury, https://doi.org/10.1016/j.injury.2020.02.070 
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s  In the humerus, 1 case was treated by cast alone and 3 with nails.
In the tibia, there were 2N, 5P and 6EF cases. A total of 57% (16/28)
cases had history of osteosynthesis changes (8 femurs, 2 humerus,
and 6 tibias) and 36% (10/28) had history of locking screw removal
(5 femoral, 1 humeral, 4 tibial fractures). The main reported com-
plication after initial fixation was neurological injury (6/28 cases),
4 of them in the femur, and infection (7/28 cases), 6 of them in the
tibia. No significant differences were found among affected bones
for initial treatment of the fracture. 
General anaesthesia was used in 70% of the cases (8 femoral, 4
humeral, 7 tibial non-unions), and spinal anaesthesia in the rest.
About the surgical technique to treat the non-union, decortications
were performed in all femoral and humeral non-unions, and in the
majority of tibias (all but one, 92%). Excision of fibrous tissue was
also required in all tibias, 8 femurs and 2 humerus. Finally, abla-
tion of necrotic bone was reported in 5 femurs, 1 humerus, and
9 tibias. Eight treated patients (8/28, 29%) did not need changing
of the fixation when treating the non-union. The case-mix of tech-
niques N/P/EF (nail/plate/exfix) after changing the fixation during
non-union treatment in 20 cases was 5/2/0 in the femoral non-
unions, 1/2/0 in the humerus, and 5/2/3 in the tibia. The final
N/P/EF techniques in the 28 cases was 7/4/0 in the femur, 2/2/0
in the humerus, and 7/3/3 in the tibia. 
Efficacy evaluation 
A secondary end-point for early efficacy was set for the trial, to
confirm bone consolidation in the treated non-unions. Clinical and
radiological evolution was followed at 3, 6, and 12 months. Clinical
evaluation of pain under full weight-bearing was performed at 3, 6,
and 12 months through the visual analog scale (VAS), considering
clinical consolidation if pain was under the threshold of 30/100 [8] .
Radiological evaluation with radiographs (anteroposterior and lat-
eral views) was performed at 3, 6, and 12 months. Imaging with CT
sections was also performed at 3 and 6 months to more accurately
assess bone bridging, particularly in case of hardware interference.
In the study radiographs and CT sections, four cortical views
were evaluated for each bone (medial and lateral cortices in an-
teroposterior radiographic views and coronal and/or transverse CT
sections, anterior and posterior cortices in lateral radiographic
views and sagittal and/or transverse CT sections). The REBORNE
bone healing scale was estimated following this formula: REBORNE
score = (Internal cortical value + External cortical value + Anterior
cortical value + Posterior cortical value) / (4 ∗ number of evalu-
ated cortices). The value of each cortical is assigned following this
rule: 1 point if fracture unchanged, 2 points if callus but non-
continuous, 3 points if callus continuous but fracture still appar-
ent, 4 points if callus with same density as cortical, and 0 points if
cortical was non-interpretable or non-visible. The maximum con-
solidation received a score of 16 (over 16 possible points), with a
value of 1.0. The non-union was healed by bone consolidation if
the score was at or above 11 points (11/16) with a value of 0.6875.
Imaging was initially evaluated for consolidation by the partic-
ipating clinicians and incorporated in the case report forms (CRF).
However, to avoid any evaluation bias, all the images were sent
to the coordinating investigator and an adjudication committee
was set with three experienced orthopaedic surgeons to adjudicate
each consolidation. 
Bone biopsies were done only in two cases that required screw
removal, at the time of this surgical procedure, upon the recom-
mendation of Ethical Committees to avoid other invasive evalua-
tion. 
Efficacy results were expressed by clinical consolidation, with
values under 30 in the VAS scale meaning no or mild pain, and
by radiological consolidation at adjudication with a REBORNE score
over 11/16 points (value of or above 0.6875). Please cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ ,tatistical analysis 
Data were described and analyzed using STATA software ver-
ion 12 (StataCorp. 2011. Texas, USA.) by the non-union anatomical
ite. Differences in frequency were evaluated by the Fisher’s exact
est. Comparison of means were performed with the Student’s t
est, Mann-Whitney test, ANOVA (one way) test, or Kruskal-Wallis
est, as deemed appropriate, with 95% of significance level. Mixed
odels for Repeated Measurements (MMRM) were generated to
stimate the mean and confidence intervals (95%) of the REBORNE
one Healing scale. Consolidation (under 30 in VAS scale and more
han 0.6875 in the REBORNE scale) were analyzed in the following
ubgroups: affected bone (femur, humerus, tibia), gender (male, fe-
ale), history of smoking habit (yes, no), and months since acute
racture. Within these, Spearman correlation tests (adjusted by
onferroni) were performed, correlating the VAS pain scale with
he REBORNE radiological scale. 
esults 
fficacy endpoint 
Clinical and radiological consolidation was observed in all 25
atients finishing the follow-up of one year (1 patient died due
o unrelated disease after six months, with the non-union healed),
nd in 26 out of 28 patients that were treated and evaluated under
TT until end of follow-up or study drop-out. Two patients were
nterpreted as failure. One of these patients voluntarily abandoned
he study at three months to request treatment (plate removal) in
 different hospital. The second patient was considered a failure at
ix months and the non-union required a new intervention (new
ecortication and hardware exchange, adding bone marrow con-
entrate) by the surgeon in charge. 
Clinical consolidation evaluated by the VAS scale (threshold of
0 out of 100) was 24/28 (85.7%) at 3 months (mean ± SD scale
alue 20.8 ± 20.7, range 0.0-76.0), 24/27 (88.9%) at 6 months
13.3 ± 15.0, range 0.0-50.0), and 25 out of 25 patients that com-
leted the follow-up at 12 months (6.6 ± 7.4, range 0.0-30.0).
hile all locations showed average VAS scale values under the
0/100 threshold, pain was lowest in the later follow-up, and at
ny follow-up visit when the humerus was treated. 
Progression of radiological consolidation, estimated by the RE-
ORNE bone healing scale (threshold of 0.6875, or 11/16 points)
or 3, 6, and 12 months, was summarized in Fig. 2 . The mean ± SD
EBORNE score changed from 0.62 ± 0.08 (range 0.45–0.83) at
 months, to 0.78 ± 0.09 (range 0.56–1) at six months, and to
.89 ±0.09 (range 0.71–1) at 12 months. 
At 3 months, the radiological healing rate was 25.0% (7/28
ases), while at 6 months it had raised to 67.8% (19/28 cases in-
luding the extrapolation of one failure and one drop-out not pre-
iously healed). At one year, the clinical healing rate was 92.8%
26/28 cases including the drop-out extrapolation of two failures
ot healed before 3 and 6 months, and one patient with proto-
ol deviation who suffered from unrelated exitus before 12 months
ut who was previously healed at 6 months). Fig. 3 displays typ-
cal cases of treated non-unions in the femur, humerus, and tibia.
he variation between the VAS scale and the REBORNE scale pro-
uced a Rho = -28% ( p = 0.0 0 0), including all follow-up visits after
urgery. 
one biopsies 
After histopathological evaluation, bone biopsies confirmed
one formation surrounding the bioceramic granules with the
ttached, expanded MSCs delivered into the non-union site at
urgery ( Fig. 4 ). Lamellar bone and osteoid tissues were found in. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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she vicinity of the BCP granules. Multinucleated giant cells labeled
y the antibody CD68 and TRAP staining were primarily located
urrounding the BCP biomaterial. These cells are considered osteo-
lasts with a pivotal role in bone regeneration, as demonstrated in
reclinical studies [ 9 , 10 ]. 
ubgroup analysis 
Analysis per bone (femur, humerus, tibia, as seen in graphs dis-
layed in Fig. 5 ) confirmed that all locations showed consolida-
ion at one year, although this was delayed in tibial non-unions
Rho tibia = -28%, Rho femur = -34%). The mean ± SD score of
he VAS/REBORNE relation in femoral non-unions progressed from
4.1 ± 20.6/0.64 ± 0.06 at 3 months, to 12.8 ± 14.1/0.79 ± 0.09
t 6 months and to 6.9 ± 8.9/0.88 ± 0.09 at 12 months. In
umeral non-unions, at 3 months the VAS/REBORNE relation was
.0 ± 10.0/0.65 ± 0.05, at 6 months 0 ± 0/0.83 ± 0.09, and at
2 months 0 ± 0/0.94 ± 0.06. In tibias, the VAS/ REBORNE score
elation changed from 23.18 ± 22.3/0.62 ± 0.10 at 3 months, to
8.7 ± 16.2/0.75 ± 0.11 at 6 months, and to 7.5 ± 6.3/0.87 ± 0.11
t 12 months. At six months, every humerus and all but one femur
ere consolidated, while four tibias were not yet seen as consoli-
ated. 
For male gender, the mean ± SD score for the VAS/REBORNE
elation was 15.9 ± 19.8/0.62 ± 0.07 at 3 months,
1.6 ± 14.8/0.77 ± 0.09 at 6 months, and 7.1 ± 8.4/0.89 ± 0.08
t 12 months. For female gender, the VAS/REBORNE relation was
7.3 ± 20.9/0.64 ± 0.09 at 3 months, 16.2 ± 15.8/0.79 ± 0.10
t 6 months, and 5.9 ± 6.3/0.87 ± 0.10 at 12 months. Specific
ubgroup analysis per gender ( Fig. 6 ) showed no significant gender
ifference in consolidation at any time, although the correlation
etween VAS scale and REBORNE scale was 15% higher in females. 
Consolidation was also compared in smoking patients (Rho = -
5%) versus non-smokers (Rho = -19%) ( Fig. 7 ). For smoking pa-
ients, the mean ± SD score of the VAS/REBORNE relation was
4.0 ± 22.4/0.61 ± 0.06 at 3 months, 13.8 ± 15.4/0.73 ± 0.07 at 6
onths, and 7.1 ± 9.4/0.85 ± 0.07 at 12 months. For non-smoking
atients, the VAS/REBORNE relation was 17.5 ± 19.2/0.66 ± 0.08
t 3 months, 12.8 ± 15.3/0.83 ± 0.10 at 6 months, and
.1 ± 4.8/0.93 ± 0.09 at 12 months. Significant differences wereig. 2. Efficacy results, mean values (with confidence interval 95%) of radiological conso
olidation at 0.6875, or 11/16 points) after adjudication of bone consolidation on imaging
Please cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ ,ound at 6 months (more consolidation scale value in non-smoking
atients, p = 0.012, t-test) and at 12 months (more consolidation
lso in non-smoking patients, p = 0.011, t-test). 
Finally, longer time elapsed after the initial fracture did not pre-
lude the occurrence of consolidation (Rho = 0.019, p = 0.729)
 Fig. 8 ). 
iscussion 
This study proved efficacy, by means of clinical and radiological
onsolidation, in femoral, humeral and tibial non-unions surgically
reated with a combination of bioceramics and expanded autolo-
ous hBM-MSCs. Although clinical consolidation (no or mild pain)
as early seen (more than 80% at 3 months), radiological consol-
dation estimated by a bone healing score was 25% at 3 months,
7% at 6 months, and only at 12 months, a 92% radiological con-
olidation was confirmed. 
Long bone non-union treatment is always a challenge, due to
he frequent multifactorial underlying cause [11–16] . While surgi-
al treatment by means of appropriate fixation is frequently suc-
essful in case of hypertrophic non-unions, biological support is
trictly needed when the non-union is not hypertrophic, confirm-
ng a certain limitation to regenerate bone at the injury site. The
linical standard biological support, the iliac crest autograft, is sel-
om evaluated for efficacy, while downsides are being recently
tressed [17] . Its use as a control to new proposals of biological
nhancement [18] provides some efficacy data. When evaluated
pon rigorous radiological criteria (3 out of 4 cortices), the auto-
raft efficacy was set at 74% consolidation at 9 months [19] . In the
ame publication, the general adjudication of radiological consoli-
ation was considered 84% with autograft, when only one cortical
ridging was interpreted as consolidation. This confirms the lim-
ted clinical evidence in autograft efficacy evaluation, and the diffi-
ulties to interpret efficacy without rigorous methods. 
Current alternative biological augmentation to treat non-unions
rovide efficacy in studies of osteoinduction, particularly by bone
orphogenetic protein –BMP- clinically available in forms 2 and
 as recombinant human BMP [ 18 , 19 ], and studies on osteogen-
sis through different cell therapy techniques [ 5 , 6 ]. The literature
n the mentioned topics very seldom provides clinical and radio-lidation for all cases based on the REBORNE consolidation scale (threshold of con- 
 for 3, 6 and 12 months. 
. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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Fig. 3. Radiographs and CT sections of clinical cases in the trial; (a) femur nonunion AP view prior to the treatment; (b) same femur postop (c) femur treated nonunion 
coronal section at 6 months; (d) femur treated nonunion AP view at 12 months; (e) humerus nonunion AP view prior to the treatment; (f) same humerus postop; (g) 
humerus treated nonunion coronal section at 6 months; (h) humerus treated nonunion AP view at 12 months; h) tibia nonunion AP view prior to the treatment; (i) same 
tibia postop; (j) tibia treated nonunion coronal section at 6 months; (k) tibia treated nonunion AP view at 12 months. 
Please cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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Fig. 3. Continued 
Fig. 4. Histology of bone biopsies from the callus formed after 8 months, (a) hematoxylin-eosin, (b) Masson trichrome, (c) immunohistochemistry with CD68, (d) TRAP 
staining (objective x20, ∗ shows the bioceramic granules). 
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w  ogical results in well controlled cases. Non-union treatment with
hBMP-7 has confirmed an efficacy of 81% healing at 5 months,
ithout structured radiological evaluation but confirmed at 5 years
19] , while a different study on BMP-7 confirmed only 63% healing
t 9 months, after a rigorous radiological evaluation [18] . Result
ariability may originate in the case mix but also in the radiologi-
al evaluation. A recent review of percutaneous injection of autol-
gous BM from different authors and techniques showed a general
nion rate of 82.4% (range 57–94%) with a mean time to achieve
olid union of 4.8 months (range 2.5–8.1) [20] . Difficulties to stan-
ardize the included non-unions, the treatment, and the evaluation
artly justify wide efficacy ranges. t  
Please cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ ,Discrepancy of clinical and radiological consolidation is a fre-
uent finding. In our study, clinical consolidation was early ob-
ained, but radiological consolidation was not evident. This fact
as prompted the use of radiological scales, mostly oriented and
alidated for fracture healing evaluation [21] . Very seldom scales
re applied to non-union healing. Union rates were clinically and
adiologically assessed [20] in a series of patients with failed
emoral shaft aseptic non-union, treated with percutaneous au-
ologous bone marrow grafting [22] . Radiographic union was di-
gnosed in this series with a score ≥10 according to the Radio-
raphic Union Scale in Tibial fractures (RUST), although the RUST
as initially designed for tibial fractures with intramedullary fixa-
ion [23] , and detected in 8/16 patients (50%) at one year follow-. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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Fig. 5. Subgroup analysis for anatomical site of the nonunion including femur, humerus and tibia (values from pain VAS –y axis- and mean REBORNE consolidation scale 
values –x axis-) at 3, 6, and 12 months follow-up. Note clinical consolidation is considered below the VAS value of 30, and imaging consolidation pass the REBORNE score 
value of 0.6875. 
Fig. 6. Subgroup analysis for gender including nonunions treated in male and female patients (values from pain VAS –y axis- and mean REBORNE consolidation scale values 
–x axis-) at 3, 6, and 12 months FU. Note clinical consolidation is considered below the VAS value of 30, and imaging consolidation pass the REBORNE score value of 0.6875. 
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U  
M  up. Bone marrow grafting significantly increased the radiographic
score with early bone formation up to union at an average of
5.0 ± 1.75 months in healed patients, and also increased the lo-
cal bone production even in patients who did not heal. Our re-
sults confirm early bone formation, but the advantage of expanded
cells seems more related to the progression towards union also inPlease cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ ,hose patients that were not early healed. In agreement to those
uthors and the original publication of Hernigou et al. [22] , effi-
acy to consolidate may be related to the number of available os-
eoprogenitors, expanded cells ATMPs providing higher numbers.
nderreporting of trials about non-unions treated with expanded
SC [6] suggest that more information is required to adequately. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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Fig. 7. Subgroup analysis for tobacco use including nonunions treated in non-smokers and smoker patients (values from pain VAS –y axis- and mean REBORNE consolidation 
scale values –x axis-) at 3, 6, and 12 months FU. Note clinical consolidation is considered below the VAS value of 30, and imaging consolidation pass the REBORNE score 
value of 0.6875. 
Fig. 8. Analysis of time since initial, acute fracture (in months, y axis) on consolidation at 3, 6, and 12 months FU (mean REBORNE consolidation scale values). Note imaging 
consolidation is considered pass the REBORNE score value of 0.6875 ( x axis). 
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i  rame the role of expanded MSCs in non-union healing, but our
esults are encouraging. 
Timing to establish consolidation is an important issue about
fficacy. We confirmed through rigorous radiological evaluation at
2 months a well-established bone healing in 90% of the cases,
ut uncertain at 6 months (67%) and improbable at 3 months inPlease cite this article as: E. Gómez-Barrena, N. Padilla-Eguiluz and P
cells (MSC) combined to biomaterials to treat long bone non-unions ✰ ,any cases (only 25% healed). Intermediate results to speak about
arly efficacy also require appropriate radiological evaluation. Bone
arrow injection obtained consolidation at about 5 months of 50%
f non-unions [20] , but the rest were not healed at 12 months.
ther treatment options, such as BMP-7, also claim early heal-
ng of 5.2 average months (range 3-10) in 81% aseptic non-unions. Rosset et al., Early efficacy evaluation of mesenchymal stromal 
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 [19] , although unfortunately the radiological evaluation was not
based on a scale. Using cortical bridging as the radiological criteria
[18] at 9 months, 75% of the tibial non-unions treated with BMP-7
were healed if considering bone bridging in one view, and 63% if
considering bridging in 3 out of 4 views. When non-union heal-
ing incorporated different treatments (femoral non-union after in-
tramedullary nail treated with plate and bone grafting), 7.2 months
(range 5-11) were needed [24] . When different bones (tibia, femur,
humerus) were treated by different techniques [25] , the average
time to healing in the successful cases averaged 6 months (range
4-8). These authors also reported earlier healing in the humerus
(average 16 weeks, range 6-36) [26] , congruently with our series
where the humeral non-unions healed significantly earlier than
femoral and tibial non-unions. The affected bone may then impact
in the non-union treatment efficacy and time to heal, as shown in
our results. In the upper limb, other reports [27] confirm that heal-
ing may occur under 6 months, while femur [24] and tibia [18] fre-
quently heal above 6 and even 9 months. 
Another factor considered in our study that may impact efficacy
is gender difference that could justify more disability observed in
females after severe accidents [4] . This was not confirmed in our
study, and other authors [19] also found similar efficacy in treating
males and females. Chronicity of the non-union, measured in time
since the original fracture, did not influence efficacy in our study,
which is a consistent finding with that of Papaniagiotu et al. after
a multilevel regression analysis [19] . 
Smoking habits have been associated with delayed consolida-
tion of tibial open fractures [28] . Tobacco use has been reported
as a risk factor for non-union, either after open or close fractures
[29] , although this association did not consider infection in the
model and tobacco influence could be overestimated [30] . Our data
confirmed that tobacco use influenced but did not jeopardize final
consolidation in our patients. This is in accordance with cell stud-
ies confirming the presence of osteoprogenitors and its capacity to
undergo osteoblastic differentiation despite tobacco use [31] . 
Our study sustains several limitations. First is the study design,
where a comparative, randomized study with controls would offer
higher evidence. This comparative randomized study is already on
its way [32] . The variability related to the fracture and to the pa-
tient is a limitation, as the trial evaluates an autologous treatment
with different osteogenic potential of individual patients. And fi-
nally, the number of cases is short, given the fact that this is an
early trial. More cases are required to ascertain efficacy, particu-
larly in some subgroups, and this can be considered an exploratory
trial for efficacy. 
Conclusion 
Bone consolidation was efficaciously obtained with the tested
expanded hBM-MSCs combined to biomaterials, by clinical and ra-
diological evaluation, better defined at 12 months. Bone regenera-
tion was confirmed by bone biopsies. No difference was observed
among the affected bones to reach consolidation, although it was
slower in tibial non-unions. Lower consolidation scores were seen
in smokers at 6 and 12 months. No influence was detected by the
gender or by the timing since the original fracture. 
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